Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's transition from commissioning to early utilization at its Galesburg facility. Burcon completed commissioning and launched commercial production of Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein during fiscal year 2026. Revenue grew sequentially to $0.83 million in the fourth quarter of fiscal 2026, up from $0.74 million in the third quarter. Management indicated that current-quarter sales are tracking toward approximately 50% sequential growth based on April and May activity. Additionally, Burcon set a new production record, with daily output roughly 60% above January through March levels.
The ramp-up in production volume is expected to drive margin improvement through better utilization of fixed costs, steadier production cadence, and the removal of start-up costs from the run-rate cost structure. This margin opportunity is more reliant on operational efficiency than on pricing alone. Customer traction is broadening, with over 30 purchasing customers and more than 200 active projects across pea, canola, and fava protein applications. The company's funding supports the Galesburg scale-up, with $6.9 million completed, $3.0 million undrawn, and management targeting $10 million in calendar year 2026 sales.
For more details, view the full announcement here. Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets (member FINRA), offers a full spectrum of investment banking services for public and private companies.
